Kevin John Conway - 02 Feb 2026 Form 4 Insider Report for Generation Bio Co. (GBIO)

Reporting relationship: Chief Financial Officer
Issuer ticker: GBIO
Reported as of: 02 Feb 2026
Net transaction value: -$406
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:05:30 UTC
Prior SEC filing: 16 Jan 2026
Next SEC filing: 09 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawna-Gay White, Attorney-in-Fact

Key filing fact

Kevin John Conway filed Form 4 for Generation Bio Co. (GBIO) on 04 Feb 2026.

Key facts

This page summarizes Kevin John Conway's Form 4 filing for Generation Bio Co. (GBIO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 16 Jan 2026.
Current net transaction value: -$406.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002051408 Primary reporting owner

Conway Kevin John

Relationship: Chief Financial Officer
Address: C/O GENERATION BIO CO., 301 BINNEY ST, SUITE 401, CAMBRIDGE
Signature: /s/ Shawna-Gay White, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +235
Change %: +12%
Price
Shares after: 2,144
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1

GBIO transaction

Common Stock

Tax liability

Transaction value: $406
Shares: -72
Change %: -3.4%
Price: $5.64
Shares after: 2,072
Date: 02 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -235
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 235
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of the company's common stock.

Footnote F2

2. The grant of 9,390 restricted stock units was made on January 20, 2023. Pursuant to the terms of that certain Agreement and Plan of Merger, by and among the Issuer, XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp., dated as of December 15, 2025 (the "Merger Agreement"), prior to the effective time of the merger as contemplated by the Merger Agreement, each restricted stock unit of the Issuer that was outstanding and unvested became vested in full on February 2, 2026.